tetano
Editor, Senior Moderator
Ther Adv Vaccines Immunother
. 2022 Aug 9;10:25151355221115009.
doi: 10.1177/25151355221115009. eCollection 2022.
Clinical profile of ChAdOx1 nCoV-19- and BBV152-vaccinated individuals among hospitalized COVID-19 patients: a pair-matched study
Vishakh C Keri[SUP] 1 [/SUP], Bharathi Arunan[SUP] 1 [/SUP], Parul Kodan[SUP] 2 [/SUP], Manish Soneja[SUP] 2 [/SUP], Neeraj Nischal[SUP] 3 [/SUP], Ashwin Varadarajan[SUP] 1 [/SUP], Akansha Didwania[SUP] 1 [/SUP], Brunda R L[SUP] 4 [/SUP], Anivita Aggarwal[SUP] 1 [/SUP], Pankaj Jorwal[SUP] 2 [/SUP], Arvind Kumar[SUP] 2 [/SUP], Animesh Ray[SUP] 2 [/SUP], Prayas Sethi[SUP] 2 [/SUP], Ved Prakash Meena[SUP] 2 [/SUP], Puneet Khanna[SUP] 5 [/SUP], Akhil Kant Singh[SUP] 5 [/SUP], Richa Aggarwal[SUP] 5 [/SUP], Kapil Dev Soni[SUP] 5 [/SUP], Alpesh Goyal[SUP] 6 [/SUP], Animesh Das[SUP] 7 [/SUP], Anjan Trikha[SUP] 5 [/SUP], Naveet Wig[SUP] 2 [/SUP]
Affiliations
Abstract
Background: COVID-19 infections among severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-vaccinated individuals are of clinical concern, especially in those requiring hospitalization. Such real-world data on ChAdOx1 nCoV-19- and BBV152-vaccinated individuals are scarce. Hence, there is an urgent need to understand their clinical profile and outcomes.
Methods: A 1:1 pair-matched study was performed among vaccinated and unvaccinated COVID-19 patients admitted between March 2021 and June 2021 at a tertiary care centre in New Delhi, India. The vaccinated group (received at least one dose of ChAdOx1 nCoV-19 or BBV152) was prospectively followed till discharge or death and matched [for age (±10 years), sex, baseline disease severity and comorbidities] with a retrospective group of unvaccinated patients admitted during the study period. Paired analysis was done to look for clinical outcomes between the two groups.
Results: The study included a total of 210 patients, with 105 in each of the vaccinated and unvaccinated groups. In the vaccinated group, 47 (44.8%) and 58 (55.2%) patients had received ChAdOx1 nCoV-19 and BBV152, respectively. However, 73 patients had received one dose and 32 had received two doses of the vaccine. Disease severity was mild in 36.2%, moderate in 31.4% and severe in 32.4%. Two mortalities were reported out of 19 fully vaccinated individuals. All-cause mortality in the vaccinated group was 8.6% (9/105), which was significantly lower than the matched unvaccinated group mortality of 21.9% (23/105), p = 0.007. Vaccination increased the chances of survival (OR = 3.8, 95% CI: 1.42-10.18) compared to the unvaccinated group.
Conclusion: In the second wave of the pandemic predominated by delta variant of SARS CoV-2, vaccination reduced all-cause mortality among hospitalized patients, although the results are only preliminary.
Keywords: BBV152; COVID-19; ChAdOx1 nCoV-19; hospitalization; vaccine.
. 2022 Aug 9;10:25151355221115009.
doi: 10.1177/25151355221115009. eCollection 2022.
Clinical profile of ChAdOx1 nCoV-19- and BBV152-vaccinated individuals among hospitalized COVID-19 patients: a pair-matched study
Vishakh C Keri[SUP] 1 [/SUP], Bharathi Arunan[SUP] 1 [/SUP], Parul Kodan[SUP] 2 [/SUP], Manish Soneja[SUP] 2 [/SUP], Neeraj Nischal[SUP] 3 [/SUP], Ashwin Varadarajan[SUP] 1 [/SUP], Akansha Didwania[SUP] 1 [/SUP], Brunda R L[SUP] 4 [/SUP], Anivita Aggarwal[SUP] 1 [/SUP], Pankaj Jorwal[SUP] 2 [/SUP], Arvind Kumar[SUP] 2 [/SUP], Animesh Ray[SUP] 2 [/SUP], Prayas Sethi[SUP] 2 [/SUP], Ved Prakash Meena[SUP] 2 [/SUP], Puneet Khanna[SUP] 5 [/SUP], Akhil Kant Singh[SUP] 5 [/SUP], Richa Aggarwal[SUP] 5 [/SUP], Kapil Dev Soni[SUP] 5 [/SUP], Alpesh Goyal[SUP] 6 [/SUP], Animesh Das[SUP] 7 [/SUP], Anjan Trikha[SUP] 5 [/SUP], Naveet Wig[SUP] 2 [/SUP]
Affiliations
- PMID: 35966176
- PMCID: PMC9373121
- DOI: 10.1177/25151355221115009
Abstract
Background: COVID-19 infections among severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-vaccinated individuals are of clinical concern, especially in those requiring hospitalization. Such real-world data on ChAdOx1 nCoV-19- and BBV152-vaccinated individuals are scarce. Hence, there is an urgent need to understand their clinical profile and outcomes.
Methods: A 1:1 pair-matched study was performed among vaccinated and unvaccinated COVID-19 patients admitted between March 2021 and June 2021 at a tertiary care centre in New Delhi, India. The vaccinated group (received at least one dose of ChAdOx1 nCoV-19 or BBV152) was prospectively followed till discharge or death and matched [for age (±10 years), sex, baseline disease severity and comorbidities] with a retrospective group of unvaccinated patients admitted during the study period. Paired analysis was done to look for clinical outcomes between the two groups.
Results: The study included a total of 210 patients, with 105 in each of the vaccinated and unvaccinated groups. In the vaccinated group, 47 (44.8%) and 58 (55.2%) patients had received ChAdOx1 nCoV-19 and BBV152, respectively. However, 73 patients had received one dose and 32 had received two doses of the vaccine. Disease severity was mild in 36.2%, moderate in 31.4% and severe in 32.4%. Two mortalities were reported out of 19 fully vaccinated individuals. All-cause mortality in the vaccinated group was 8.6% (9/105), which was significantly lower than the matched unvaccinated group mortality of 21.9% (23/105), p = 0.007. Vaccination increased the chances of survival (OR = 3.8, 95% CI: 1.42-10.18) compared to the unvaccinated group.
Conclusion: In the second wave of the pandemic predominated by delta variant of SARS CoV-2, vaccination reduced all-cause mortality among hospitalized patients, although the results are only preliminary.
Keywords: BBV152; COVID-19; ChAdOx1 nCoV-19; hospitalization; vaccine.